The effect of hypothermia dose on vasopressor requirements and outcome after cardiac arrest

Objectives: We evaluated the association between TH use and dose and cumulative vasopressor and inotrope requirement, survival, and neurologic outcome. Background: Therapeutic hypothermia (TH) improves outcome after cardiac arrest, but may increase vasopressor and inotrope requirements. Methods: Chart review of in- and out-of-hospital cardiac arrests between 1/1/2005 and 3/15/2010. Data included demographic information, category of post-cardiac arrest illness severity ((I) awake, (II) coma (not following commands but intact brainstem responses) + mild cardiopulmonary dysfunction (SOFA [Sequential Organ Failure Assessment] cardiac + respiratory score <4), (III) coma + moderate-severe cardiopulmonary dysfunction (SOFA cardiac + respiratory score >= 4), and (IV) coma without brainstem reflexes), cumulative vasopressor index (CVI), inotrope use, survival, and neurologic outcome. The dose of TH (hours * temperature below threshold) was calculated using thresholds of <= 34 degrees C and <= 35 degrees C. Data were analyzed using descriptive statistics, Student's t-test, Wilcoxon test, and chi-squared analysis. Linear and logistic regression evaluated the effect of hypothermia dose on total CVI, survival and neurologic outcome. Results: Among 361 comatose patients, 233 (65%) received TH. Vasopressor administration (measured by CVI) was higher in normothermic subjects (60.2% vs. 46.4%; p = 0.016). Using a 34 degrees C threshold, SOFA respiratory subscore and PEA arrest predicted total CVI. Using a 35 degrees C threshold, severity of coma, SOFA respiratory subscore, PEA arrest and use of inotropic agents in addition to vasopressors predicted total CVI. Initial motor examination predicted survival and neurologic outcome, while TH dose did not. Conclusions: TH delivery is not associated with vasopressor requirement. TH dose is not associated with total CVI, survival, or good outcome. Vasopressor or inotropic requirement should not contraindicate TH use. (C) 2012 Elsevier Ireland Ltd. All rights reserved.